Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies

References

• Recio R, Mancheño M, Viedma E, et al. Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence. Antimicrob Agents Chemother. 2020;64(2). doi:10.1128/AAC.01759-19
   PubMed Web of Science ®Google Scholar
• Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707–719. doi:10.1080/14787210.2022.2020099
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen X-L, Huang A-W, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect. 2016;5(3):e27. doi:10.1038/emi.2016.22
   PubMedGoogle Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–1283. doi:10.1093/cid/ciu052
   PubMed Web of Science ®Google Scholar
• Wei X, Li L, Li M, et al. Risk factors and outcomes of patients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infection. Infect Drug Resist. 2023;16:337–346. doi:10.2147/IDR.S396428
   PubMed Web of Science ®Google Scholar
• Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009;31(2):146–150. doi:10.1097/SHK.0b013e318182f98f
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Yangco B. CDC definitions for nosocomial infections. Am J Infect Control. 1989;17(1):42–43. doi:10.1016/S0196-6553(89)80013-6
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250–1256. doi:10.1097/01.CCM.0000050454.01978.3B
   PubMed Web of Science ®Google Scholar
• George B, Seals S, Aban I. Survival analysis and regression models. J Nucl Cardiol. 2014;21(4):686–694. doi:10.1007/s12350-014-9908-2
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4). doi:10.1128/CMR.00031-19
   PubMed Web of Science ®Google Scholar
• Wang MG, Liu Z-Y, Liao X-P, et al. Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa. Antibiotics. 2021;10(5):548. doi:10.3390/antibiotics10050548
   Google Scholar
• Al-Orphaly M, Hadi HA, Eltayeb FK, et al. Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa Region. mSphere. 2021;6(3). doi:10.1128/mSphere.00202-21
   PubMed Web of Science ®Google Scholar
• Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP. In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals. J Thorac Dis. 2019;11(5):1896–1902. doi:10.21037/jtd.2019.05.13
   PubMed Web of Science ®Google Scholar
• Woodworth KR, Walters MS, Weiner LM, et al. Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms — United States, 2006–2017. MMWR Morb Mortal Wkly Rep. 2018;67(13):396–401. doi:10.15585/mmwr.mm6713e1
   PubMed Web of Science ®Google Scholar
• Chaves L, Tomich LM, Salomão M, et al. High mortality of bloodstream infection outbreak caused by carbapenem-resistant P. aeruginosa producing SPM-1 in a bone marrow transplant unit. J Med Microbiol. 2017;66(12):1722–1729. doi:10.1099/jmm.0.000631
   PubMed Web of Science ®Google Scholar
• Teelucksingh K, Shaw E. Clinical characteristics, appropriateness of empiric antibiotic therapy, and outcome of Pseudomonas aeruginosa bacteremia across multiple community hospitals. Eur J Clin Microbiol Infect Dis. 2022;41(1):53–62. doi:10.1007/s10096-021-04342-y
   PubMed Web of Science ®Google Scholar
• Lee CC, Wang J-L, Lee C-H, et al. Age-related trends in adults with community-onset bacteremia. Antimicrob Agents Chemother. 2017;61(12). doi:10.1128/AAC.01050-17
   Web of Science ®Google Scholar
• Liu KS, Tong Y-S, Lee M-T, et al. Risk factors of 30-day all-cause mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. J Pers Med. 2021;11(7):616. doi:10.3390/jpm11070616
   PubMed Web of Science ®Google Scholar
• Chen L, Han X, Li Y, et al. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant enterobacterales. Antimicrob Agents Chemother. 2021;65(9):e0069821. doi:10.1128/AAC.00698-21
   PubMed Web of Science ®Google Scholar
• Meng H, Han L, Niu M, et al. Risk factors for mortality and outcomes in hematological malignancy patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Infect Drug Resist. 2022;15:4241–4251. doi:10.2147/IDR.S374904
   PubMed Web of Science ®Google Scholar
• Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother. 2013;68(6):1431–1438. doi:10.1093/jac/dkt002
   PubMed Web of Science ®Google Scholar
• Thaden JT, Park LP, Maskarinec SA, et al. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria. Antimicrob Agents Chemother. 2017;61(6). doi:10.1128/AAC.02671-16
   Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, et al. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31. doi:10.1016/j.jiph.2018.08.002
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Fan X, et al. Prevalence of resistant gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study. Medicine. 2015;94(45):e1931. doi:10.1097/MD.0000000000001931
   PubMed Web of Science ®Google Scholar
• Roch M, Sierra R, Andrey DO. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. Clin Microbiol Infect. 2023;29(3):320–325. doi:10.1016/j.cmi.2022.10.018
   PubMed Web of Science ®Google Scholar
• Papst L, Beović B, Pulcini C, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070–1076. doi:10.1016/j.cmi.2018.01.015
   PubMed Web of Science ®Google Scholar
• Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104–5111. doi:10.1128/AAC.01230-13
   PubMed Web of Science ®Google Scholar
• Ramos JF, Leite G, Martins RCR, et al. Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro. Eur J Clin Microbiol Infect Dis. 2022;41(2):313–317. doi:10.1007/s10096-021-04361-9
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/S1473-3099(18)30099-9
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother. 2005;55(6):954–957. doi:10.1093/jac/dki153
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin Microbiol Infect. 2006;12(4):315–321. doi:10.1111/j.1469-0691.2005.01351.x
   PubMed Web of Science ®Google Scholar
• Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.02431-18
   Web of Science ®Google Scholar
• Nichols WW, de Jonge BLM, Kazmierczak KM, et al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother. 2016;60(8):4743–4749. doi:10.1128/AAC.00220-16
   PubMed Web of Science ®Google Scholar
• Testa R, Cantón R, Giani T, et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents. 2015;45(6):641–646. doi:10.1016/j.ijantimicag.2014.12.033
   PubMed Web of Science ®Google Scholar
• Chen J, Liang Q, Chen X, et al. Ceftazidime/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection. Infect Drug Resist. 2022;15:655–667. doi:10.2147/IDR.S350976
   PubMed Web of Science ®Google Scholar
• Shi Y. [Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)]. Zhonghua Jie He He Hu Xi Za Zhi. 2022;45(8):739–752. Chinese. doi:10.3760/cma.j.cn112147-20220407-00290
   PubMedGoogle Scholar